All In Biotech

Free tool

FAERS Monitor: Vtama

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215272 or its brand name (Vtama, Tapinarof). Reports on generic versions are filed under their own applications.

Reports

1,974

Serious

205

10% of reports

Hospitalization

64

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • folliculitis292
  • pruritus238
  • headache182
  • rash152
  • dermatitis contact134
  • drug ineffective130
  • erythema124
  • skin burning sensation87
  • psoriasis77
  • application site erythema63
  • off label use63
  • application site pruritus62
  • application site pain60
  • dry skin56
  • skin exfoliation54

Reports by year received

View as table
YearReports
20191
20203
20214
2022192
2023664
2024506
2025263
2026341

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,185 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
folliculitisSignal292305.2274.085,815
dermatitis contactSignal134126.6107.416,393
application site pruritusSignal6229.222.81,657
application site painSignal6029.122.71,597
application site erythemaSignal6325.720.11,467
skin burning sensationSignal8713.010.5950
skin exfoliationSignal546.85.2263
pruritusSignal2386.65.91,146
erythemaSignal1246.45.4568
psoriasisSignal776.35.0339
dry skinSignal564.53.5148
rashSignal1523.73.2305
headacheSignal1823.12.7264
drug ineffective1301.10.90
off label use630.80.64

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.